The application of tissue engineering in reversing mitomycin C-induced ischemic conjunctiva

Journal of Biomedical Materials Research - Part A

Volumn 100 A, Issue 5, 2012, Pages 1126-1135

  Peng, Yi Jie ^a   Pan, Chien Yi ^b   Hsieh, Yi Ting ^a,c   Wu, Semon ^d   Chu, Hsi Ning ^a   Hsu, Wei Cherng ^a,e  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d CHINESE CULTURE UNIVERSITY   (Taiwan)

^e TZU CHI UNIVERSITY   (Taiwan)

Author keywords

antimetabolite; conjunctiva; MMC; neovascularization; wound healing

Indexed keywords

ANTIMETABOLITE; CONJUNCTIVA; MMC; NEOVASCULARIZATION; WOUND HEALING;

DEFECTS; TISSUE ENGINEERING;

COLLAGEN;

ALPHA SMOOTH MUSCLE ACTIN; CD34 ANTIGEN; COLLAGEN; GLYCOSAMINOGLYCAN; MITOMYCIN C;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTERIOLE; ARTICLE; CAPILLARY; CONJUNCTIVA DISEASE; CONJUNCTIVA ISCHEMIA; CONTROLLED STUDY; DEGRADATION; EPITHELIZATION; FIBROBLAST; HISTOLOGY; IMMUNOFLUORESCENCE; IMPLANTATION; ISCHEMIA; LYMPHOCYTE; MACROPHAGE; NONHUMAN; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; RABBIT; SCAR FORMATION; THICKNESS; TISSUE ENGINEERING; VASCULARIZATION; WOUND HEALING;

ANIMALS; ANTIGENS, CD34; BIOCOMPATIBLE MATERIALS; COLLAGEN; CONJUNCTIVA; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSAMINOGLYCANS; ISCHEMIA; MITOMYCIN; RABBITS; STAINING AND LABELING; TISSUE ENGINEERING; WOUND HEALING;

EID: 84862794803     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34041     Document Type: Article

References (36)

1. Crowston JG, Akbar AN, Constable PH, Occleston NL, Daniels JT, Khaw PT,. Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci 1998; 39: 449-454. (Pubitemid 28093886)
2. Georgoulas S, Dahlmann-Noor A, Brocchini S, Khaw PT,. Modulation of wound healing during and after glaucoma surgery. Prog Brain Res 2008; 173: 237-254.
3. Chen CW, Huang HT, Lee CC,. Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma. J Ocul Pharmacol 1990; 6: 175-178.
4. Kupin TH, Juzych MS, Shin DH, Khatana AK, Olivier MM,. Adjunctive mitomycin C in primary trabeculectomy in phakic eyes. Am J Ophthalmol 1995; 119: 30-39.
5. Loon SC, Chew PT,. A major review of antimetabolites in glaucoma therapy. Ophthalmologica 1999; 213: 234-245. (Pubitemid 29331687)
6. Palmer SS,. Mitomycin as adjunct chemotherapy with trabeculectomy. Ophthalmology 1991; 98: 317-321.
7. Bindlish R, Condon GP, Schlosser JD, D'Antonio J, Lauer KB, Lehrer R,. Efficacy and safety of mitomycin-C in primary trabeculectomy: Five-year follow-up. Ophthalmology 2002; 109: 1336-1341. (Pubitemid 34700927)
8. Greenfield DS, Liebmann JM, Jee J, Ritch R,. Late-onset bleb leaks after glaucoma filtering surgery. Arch Ophthalmol 1998; 116: 443-447. (Pubitemid 28169743)
9. DeBry PW, Perkins TW, Heatley G, Kaufman P, Brumback LC,. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol 2002; 120: 297-300. (Pubitemid 34250049)
10. Francis BA, Du LT, Najafi K, Murthy R, Kurumety U, Rao N, Minckler DS,. Histopathologic features of conjunctival filtering blebs. Arch Ophthalmol 2005; 123: 166-170. (Pubitemid 40189702)
11. Belyea DA, Dan JA, Stamper RL, Lieberman MF, Spencer WH,. Late onset of sequential multifocal bleb leaks after glaucoma filtration surgery with 5-fluorouracil and mitomycin C. Am J Ophthalmol 1997; 124: 40-45. (Pubitemid 27298989)
12. Cordeiro MF, Siriwardena D, Chang L, Khaw PT,. Wound healing modulation after glaucoma surgery. Curr Opin Ophthalmol 2000; 11: 121-126. (Pubitemid 30164033)
13. Mietz H, Arnold G, Kirchhof B, Diestelhorst M, Krieglstein GK,. Histopathology of episcleral fibrosis after trabeculectomy with and without mitomycin C. Graefes Arch Clin Exp Ophthalmol 1996; 234: 364-368. (Pubitemid 26150818)
14. Nuyts RM, Felten PC, Pels E, Langerhorst CT, Geijssen HC, Grossniklaus HE, Greve EL,. Histopathologic effects of mitomycin C after trabeculectomy in human glaucomatous eyes with persistent hypotony. Am J Ophthalmol 1994; 118: 225-237. (Pubitemid 24242457)
15. Smith MF, Magauran RG III, Betchkal J, Doyle JW,. Treatment of postfiltration bleb leaks with autologous blood. Ophthalmology 1995; 102: 868-871.
16. Anand N, Khan A,. Long-term outcomes of needle revision of trabeculectomy blebs with mitomycin C and 5-fluorouracil: A comparative safety and efficacy report. J Glaucoma 2009; 18: 513-520.
17. Burnstein AL, WuDunn D, Knotts SL, Catoira Y, Cantor LB,. Conjunctival advancement versus nonincisional treatment for late-onset glaucoma filtering bleb leaks. Ophthalmology 2002; 109: 71-75. (Pubitemid 34027426)
18. Catoira Y, Wudunn D, Cantor LB,. Revision of dysfunctional filtering blebs by conjunctival advancement with bleb preservation. Am J Ophthalmol 2000; 130: 574-579.
19. Tannenbaum DP, Hoffman D, Greaney MJ, Caprioli J,. Outcomes of bleb excision and conjunctival advancement for leaking or hypotonous eyes after glaucoma filtering surgery. Br J Ophthalmol 2004; 88: 99-103. (Pubitemid 38091373)
20. Chen HS, Ritch R, Krupin T, Hsu WC,. Control of filtering bleb structure through tissue bioengineering: An animal model. Invest Ophthalmol Vis Sci 2006; 47: 5310-5314. (Pubitemid 46723780)
21. Hsu WC, Spilker MH, Yannas IV, Rubin PA,. Inhibition of conjunctival scarring and contraction by a porous collagen-glycosaminoglycan implant. Invest Ophthalmol Vis Sci 2000; 41: 2404-2411. (Pubitemid 30624363)
22. Hsu WC, Ritch R, Krupin T, Chen HS,. Tissue bioengineering for surgical bleb defects: An animal study. Graefes Arch Clin Exp Ophthalmol 2008; 246: 709-717.
23. Davis GE, Senger DR,. Endothelial extracellular matrix: Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97: 1093-1107.
24. Twardowski T, Fertala A, Orgel JP, San Antonio JD,. Type I collagen and collagen mimetics as angiogenesis promoting superpolymers. Curr Pharm Des 2007; 13: 3608-3621. (Pubitemid 350238932)
25. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME,. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008; 27: 331-371.
26. Tolentino MJ,. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Curr Mol Med 2009; 9: 973-981.
27. Callegari A, Bollini S, Iop L, Chiavegato A, Torregrossa G, Pozzobon M, Gerosa G, De Coppi P, Elvassore N, Sartore S,. Neovascularization induced by porous collagen scaffold implanted on intact and cryoinjured rat hearts. Biomaterials 2007; 28: 5449-5461. (Pubitemid 47603197)
28. Chiu LL, Radisic M,. Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues. Biomaterials 2010; 31: 226-241.
29. Nillesen ST, Geutjes PJ, Wismans R, Schalkwijk J, Daamen WF, van Kuppevelt TH,. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials 2007; 28: 1123-1131. (Pubitemid 44809425)
30. Rücker M, Laschke MW, Junker D, Carvalho C, Schramm A, Mülhaupt R, Gellrich NC, Menger MD,. Angiogenic and inflammatory response to biodegradable scaffolds in dorsal skinfold chambers of mice. Biomaterials 2006; 27: 5027-5038. (Pubitemid 43949420)
31. Siljander PR, Hamaia S, Peachey AR, Slatter DA, Smethurst PA, Ouwehand WH, Knight CG, Farndale RW,. Integrin activation state determines selectivity for novel recognition sites in fibrillar collagens. J Biol Chem 2004; 279: 47763-47772. (Pubitemid 39540925)
32. Sweeney SM, DiLullo G, Slater SJ, Martinez J, Iozzo RV, Lauer-Fields JL, Fields GB, San Antonio JD,. Angiogenesis in collagen I requires alpha2beta1 ligation of a GFP*GER sequence and possibly p38 MAPK activation and focal adhesion disassembly. J Biol Chem 2003; 278: 30516-30524. (Pubitemid 36994555)
33. Jackson CJ, Giles I, Knop A, Nethery A, Schrieber L,. Sulfated polysaccharides are required for collagen-induced vascular tube formation. Exp Cell Res 1994; 215: 294-302. (Pubitemid 24381079)
34. Jackson CJ, Jenkins KL,. Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp Cell Res 1991; 192: 319-323. (Pubitemid 121005236)
35. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA,. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998; 152: 1445-1452. (Pubitemid 28275003)
36. Li Z, Van Bergen T, Van de Veire S, Van de Vel I, Moreau H, Dewerchin M, Maudgal PC, Zeyen T, Spileers W, Moons L, Stalmans I,. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2009; 50: 5217-5225.